Author:
Ingram N,MacCormac L P,Oxley N T,Burns P A,Hall G D
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Reference30 articles.
1. Alberts DS, Markman M, Muggia F, Ozols RF, Eldermire E, Bookman MA et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol 2006; 103: 783–792.
2. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524–530.
3. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553–566.
4. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7: 839–844.
5. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562–1569.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献